Featured Article

Ken Getz of Tufts CSDD and Steve Young of CluePoints Discuss Stand Out Results from Recent RBQM Study

In part 2 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints highlight what stood out to them from the results of a recent study on RBQM adoption.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Blog
ICH E6(R3), Demystified Part 4: Informed Consent
  • From Signature to System: Why E6(R3) Raises the Bar For years, informed consent has too often...
Read More
Blog
Why RBQM Programs Stall: The Gap Between Insight and Action
  • Many organizations invest heavily in detection, analytics, dashboards, and centralized monitoring. Yet RBQM still stalls. The...
Read More
Blog
RBQM for the Mid-Market Explained
  • Mid-market sponsors are expected to meet the same ICH E6(R3) standards as large pharma, often with...
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI